ONC vs. SMMT: BeOne Medicines vs. Summit Therapeutics Stock Comparison

November 11, 2026

How do BeOne Medicines (ONC) and Summit Therapeutics (SMMT) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.

Company Profile

BeOne Medicines (ONC) and Summit Therapeutics (SMMT) are both classified in the Biotechnology sub-industry within the broader Biotechnology industry, placing them in the closest GICS peer bucket.

Summit Therapeutics (SMMT) trades as ordinary local shares, while BeOne Medicines (ONC) trades as an ADR — compare with FX exposure, depositary-program fees, and dividend-withholding-tax differences in mind.

Company profile comparison for BeOne Medicines (ONC) and Summit Therapeutics (SMMT)
Profile Item	ONC	SMMT
Name	BeOne Medicines Ltd. American Depositary Shares	Summit Therapeutics Inc.
Country/Region	Switzerland	United States
GICS Sector	Health Care	Health Care
GICS Industry Group	Pharmaceuticals, Biotechnology & Life Sciences	Pharmaceuticals, Biotechnology & Life Sciences
GICS Industry	Biotechnology	Biotechnology
GICS Sub-Industry	Biotechnology	Biotechnology
Market Capitalization	46.49 billion USD	13.06 billion USD
Currency	USD	USD
Exchange	Nasdaq	Nasdaq
Listing Date	February 3, 2016	March 5, 2015
Security Type	ADR	Common Stock

Price Performance

Cumulative Growth

ONC

SMMT

GSPC

BeOne Medicines (ONC) vs. Summit Therapeutics (SMMT), with S&P 500 (GSPC) for reference: Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…

Trailing total returns for BeOne Medicines (ONC) and Summit Therapeutics (SMMT). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…

Calendar-year total returns for BeOne Medicines (ONC) and Summit Therapeutics (SMMT). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Price performance metrics for BeOne Medicines (ONC) and Summit Therapeutics (SMMT)
Metric	ONC	SMMT
Total Return (1Y)	30.59%	-2.48%
Total Return (3Y, Annualized)	30.15%	116.18%
Total Return (5Y, Annualized)	2.48%	26.89%

Risk Profile

Drawdown History

ONC

SMMT

GSPC

BeOne Medicines (ONC) vs. Summit Therapeutics (SMMT), with S&P 500 (GSPC) for reference: Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…

Distribution of monthly total returns for BeOne Medicines (ONC) and Summit Therapeutics (SMMT). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Summit Therapeutics (SMMT) reports a negative beta of -1.51, suggesting inverse market sensitivity over the measurement window. That is uncommon for ordinary equities and can reflect commodity-linked or hedge-like exposure, but it can also come from statistical noise. BeOne Medicines (ONC) has a non-negative beta of 0.59.

Risk profile metrics for BeOne Medicines (ONC) and Summit Therapeutics (SMMT)
Metric	ONC	SMMT
Volatility (1Y, Annualized)	35.90%	75.06%
Beta (5Y)	0.59	-1.51
Max Drawdown (5Y)	-68.89%	-87.64%
Avg. Volume (3M)	405.29K	6.19M

Risk-Adjusted Performance

Risk-Return Positioning

ONC and SMMT are plotted by 1-year volatility (risk) and 1-year return. The dashed Capital Allocation Line runs from the risk-free rate through the shared industry median.

Risk-Adjusted Metrics

Risk-adjusted metrics for BeOne Medicines (ONC) and Summit Therapeutics (SMMT)
Metric	ONC	SMMT
Sharpe Ratio (1Y)	0.73	-0.09
Sortino Ratio (1Y)	1.15	-0.13

Profitability

ROE (TTM)

Summit Therapeutics (SMMT) reports a negative ROE of -220.01%; negative ROE can reflect losses or negative shareholders’ equity, so it is harder to read as capital efficiency. Meanwhile BeOne Medicines (ONC) reports 18.40%, ranking against industry peers normally.

ONC

Pharmaceuticals, Biotechnology & Life Sciences industry group

18.40%

Max: 109.18%
ONC: 18.40%
Q3: 6.23%
Median: -26.66%
Q1: -64.05%
Min: -167.77%

SMMT

Pharmaceuticals, Biotechnology & Life Sciences industry group

-220.01%

Max: 109.18%
Q3: 6.23%
Median: -26.66%
Q1: -64.05%
Min: -167.77%
SMMT: -220.01%

BeOne Medicines (ONC) vs. Summit Therapeutics (SMMT): A comparison of their ROE against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Net Margin (TTM)

BeOne Medicines (ONC) at 13.86% retains a top-quartile share of revenue as profit, ahead of Summit Therapeutics (SMMT) at 0.00%, which keeps about the industry-typical share.

ONC

Pharmaceuticals, Biotechnology & Life Sciences industry group

13.86%

Max: 18.05%
ONC: 13.86%
Q3: 4.78%
Median: 0.00%
Q1: -4.14%
Min: -17.05%

SMMT

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

Max: 18.05%
Q3: 4.78%
SMMT: 0.00%
Median: 0.00%
Q1: -4.14%
Min: -17.05%

BeOne Medicines (ONC) vs. Summit Therapeutics (SMMT): A comparison of their net margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Operating Margin (TTM)

BeOne Medicines (ONC) at 22.15% operates in the top operating margin quartile, ahead of Summit Therapeutics (SMMT) at 0.00%, which runs around its industry’s norm.

ONC

Pharmaceuticals, Biotechnology & Life Sciences industry group

22.15%

Max: 83.12%
ONC: 22.15%
Q3: 14.77%
Median: 0.00%
Q1: -78.82%
Min: -207.40%

SMMT

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

Max: 83.12%
Q3: 14.77%
SMMT: 0.00%
Median: 0.00%
Q1: -78.82%
Min: -207.40%

BeOne Medicines (ONC) vs. Summit Therapeutics (SMMT): A comparison of their operating margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Profitability Metrics

Profitability metrics for BeOne Medicines (ONC) and Summit Therapeutics (SMMT)
Metric	ONC	SMMT
ROE (TTM)	18.40%	-220.01%
ROA (TTM)	8.42%	-111.99%
Net Margin (TTM)	13.86%	0.00%
Operating Margin (TTM)	22.15%	0.00%
Gross Margin (TTM)	89.39%	0.00%

Growth

Revenue Growth

Only one side can be read here: BeOne Medicines (ONC) reports revenue growth of 40.23%, ranked against its industry; Summit Therapeutics (SMMT) has no revenue growth figure this period.

BeOne Medicines (ONC) vs. Summit Therapeutics (SMMT): A comparison of their Revenue Growth across different time periods.

EPS Growth

Neither BeOne Medicines (ONC) nor Summit Therapeutics (SMMT) reports a EPS growth value for this period, so a direct comparison isn't possible.

Growth Metrics

Growth metrics for BeOne Medicines (ONC) and Summit Therapeutics (SMMT)
Metric	ONC	SMMT
Revenue Growth (YoY)	40.23%	--
Revenue Growth (3Y CAGR)	55.69%	--
EPS Growth (YoY)	--	--
EPS Growth (3Y CAGR)	--	--

Financial Strength

Current Ratio (MRQ)

Both BeOne Medicines (ONC) at 3.55 and Summit Therapeutics (SMMT) at 5.99 carry current ratio within their industries’ typical mid-ranges, suggesting balanced short-term liquidity relative to peers.

ONC

Pharmaceuticals, Biotechnology & Life Sciences industry group

3.55

Max: 25.13
Q3: 12.13
Median: 5.52
ONC: 3.55
Q1: 2.47
Min: 0.10

SMMT

Pharmaceuticals, Biotechnology & Life Sciences industry group

5.99

Max: 25.13
Q3: 12.13
SMMT: 5.99
Median: 5.52
Q1: 2.47
Min: 0.10

BeOne Medicines (ONC) vs. Summit Therapeutics (SMMT): A comparison of their current ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Debt / Equity (MRQ)

Both BeOne Medicines (ONC) at 0.35 and Summit Therapeutics (SMMT) at 0.04 fund their balance sheets with roughly industry-typical debt-to-equity mixes.

ONC

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.35

Max: 1.42
Q3: 0.65
ONC: 0.35
Median: 0.15
Q1: 0.02
Min: 0.00

SMMT

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.04

Max: 1.42
Q3: 0.65
Median: 0.15
SMMT: 0.04
Q1: 0.02
Min: 0.00

BeOne Medicines (ONC) vs. Summit Therapeutics (SMMT): A comparison of their debt-to-equity ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Financial Strength Metrics

Financial strength metrics for BeOne Medicines (ONC) and Summit Therapeutics (SMMT)
Metric	ONC	SMMT
Current Ratio (MRQ)	3.55	5.99
Debt / Equity (MRQ)	0.35	0.04
Net Debt / EBITDA	-2.80	--

Dividends

Dividend Yield (TTM)

Neither BeOne Medicines (ONC) nor Summit Therapeutics (SMMT) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

ONC

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

ONC: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

SMMT

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

SMMT: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

BeOne Medicines (ONC) vs. Summit Therapeutics (SMMT): A comparison of their dividend yield against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Payout Ratio (TTM)

Neither BeOne Medicines (ONC) nor Summit Therapeutics (SMMT) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

ONC

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

ONC: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

SMMT

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

SMMT: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

BeOne Medicines (ONC) vs. Summit Therapeutics (SMMT): A comparison of their payout ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Metrics

Dividend metrics for BeOne Medicines (ONC) and Summit Therapeutics (SMMT)
Metric	ONC	SMMT
Dividend Yield (TTM)	0.00%	0.00%
Dividend Payout Ratio (TTM)	0.00%	0.00%

Valuation

P/E Ratio (TTM)

An earnings multiple is available for just one side: BeOne Medicines (ONC) trades at 52.17 times trailing earnings, ranked against its peers, while Summit Therapeutics (SMMT) has no P/E ratio this period.

ONC

Pharmaceuticals, Biotechnology & Life Sciences industry group

52.17

Max: 85.34
ONC: 52.17
Q3: 43.46
Median: 26.69
Q1: 13.30
Min: 0.07

SMMT

Pharmaceuticals, Biotechnology & Life Sciences industry group

Max: 85.34
Q3: 43.46
Median: 26.69
Q1: 13.30
Min: 0.07
SMMT: --

BeOne Medicines (ONC) vs. Summit Therapeutics (SMMT): SMMT does not report P/E ratio, so it has no value marker; ONC is benchmarked against the Pharmaceuticals, Biotechnology & Life Sciences industry group.

P/S Ratio (TTM)

A sales-based read is only available for BeOne Medicines (ONC), whose P/S ratio of 7.04 ranks against industry peers; Summit Therapeutics (SMMT) reports no figure this period.

ONC

Pharmaceuticals, Biotechnology & Life Sciences industry group

7.04

Max: 58.18
Q3: 25.77
Median: 7.30
ONC: 7.04
Q1: 3.01
Min: 0.01

SMMT

Pharmaceuticals, Biotechnology & Life Sciences industry group

Max: 58.18
Q3: 25.77
Median: 7.30
Q1: 3.01
Min: 0.01
SMMT: --

BeOne Medicines (ONC) vs. Summit Therapeutics (SMMT): SMMT does not report P/S ratio, so it has no value marker; ONC is benchmarked against the Pharmaceuticals, Biotechnology & Life Sciences industry group.

P/B Ratio (MRQ)

Both look rich against book: BeOne Medicines (ONC) at 7.98 sits in the upper P/B ratio quartile, and Summit Therapeutics (SMMT) at 23.13 prices even higher, above its industry range.

ONC

Pharmaceuticals, Biotechnology & Life Sciences industry group

7.98

Max: 13.53
ONC: 7.98
Q3: 6.54
Median: 3.25
Q1: 1.69
Min: -5.59

SMMT

Pharmaceuticals, Biotechnology & Life Sciences industry group

23.13

SMMT: 23.13
Max: 13.53
Q3: 6.54
Median: 3.25
Q1: 1.69
Min: -5.59

BeOne Medicines (ONC) vs. Summit Therapeutics (SMMT): A comparison of their P/B ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Valuation Metrics

Valuation metrics for BeOne Medicines (ONC) and Summit Therapeutics (SMMT)
Metric	ONC	SMMT
P/E Ratio (TTM)	52.17	--
P/S Ratio (TTM)	7.04	--
P/B Ratio (MRQ)	7.98	23.13
Free Cash Flow Yield (TTM)	2.21%	-1.64%